Free Trial
NASDAQ:PBLA

Panbela Therapeutics (PBLA) Stock Price, News & Analysis

Panbela Therapeutics logo
$0.33 +0.01 (+3.84%)
(As of 01:30 PM ET)

About Panbela Therapeutics Stock (NASDAQ:PBLA)

Key Stats

Today's Range
$0.33
$0.33
50-Day Range
$0.30
$0.40
52-Week Range
$0.30
$38.00
Volume
176 shs
Average Volume
216,580 shs
Market Capitalization
$1.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$500.00
Consensus Rating
Moderate Buy

Company Overview

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Panbela Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
22nd Percentile Overall Score

PBLA MarketRank™: 

Panbela Therapeutics scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Panbela Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Panbela Therapeutics has received no research coverage in the past 90 days.

  • Read more about Panbela Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for PBLA.
  • Dividend Yield

    Panbela Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Panbela Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for PBLA.
  • News Sentiment

    Panbela Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Panbela Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 3 people have searched for PBLA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Panbela Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.01% of the stock of Panbela Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 4.37% of the stock of Panbela Therapeutics is held by institutions.

  • Read more about Panbela Therapeutics' insider trading history.
Receive PBLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PBLA Stock News Headlines

Panbela Therapeutics Announces Q3 2024 Financial Results
JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
See More Headlines

PBLA Stock Analysis - Frequently Asked Questions

Panbela Therapeutics' stock was trading at $18.30 at the beginning of the year. Since then, PBLA stock has decreased by 98.2% and is now trading at $0.3330.
View the best growth stocks for 2024 here
.

Panbela Therapeutics, Inc. (NASDAQ:PBLA) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($159.00) earnings per share for the quarter, missing analysts' consensus estimates of ($94.20) by $64.80.

Panbela Therapeutics's stock reverse split on Thursday, January 18th 2024. The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Panbela Therapeutics investors own include Tesla (TSLA), Recursion Pharmaceuticals (RXRX), Aridis Pharmaceuticals (ARDS), Pacific Biosciences of California (PACB), Ginkgo Bioworks (DNA), Tilray (TLRY) and Agnico Eagle Mines (AEM).

Company Calendar

Last Earnings
8/10/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PBLA
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$500.00
High Stock Price Target
$500.00
Low Stock Price Target
$500.00
Potential Upside/Downside
+155,808.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-25,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($18.37) per share

Miscellaneous

Free Float
4,855,000
Market Cap
$1.56 million
Optionable
Not Optionable
Beta
1.58
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:PBLA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners